Business Development Archives | Report Store

What Does It Take To Launch And Lead An Oncology Biotech Today?

Oncolytic virus company Theolytics has emerged ready to raise a series A round and get its preclinical assets into human trials by 2021. CEO Charlotte Casebourne talks to In Vivo about the challenge of standing out from the crowd in oncology, how viruses have evolved as a treatment approach in cancer, and how oncolytic viruses might be the answer to the cancer drug pricing conundrum. Learn what this young CEO (at age 26) has to say about the skills required to be a biotech CEO today, the concerning issue of access to novel personalized cancer treatments, and the biggest challenges she sees in cancer drug development today.

Business Development

Business Development

What Does It Take To Launch And Lead An Oncology Biotech Today?

Novartis’ Zolgensma Had Manipulated Data In Application, US FDA Says

Novartis CEO Explains Delay In Telling US FDA About Zolgensma Data Fraud: We Wanted To Understand It First

Sanofi Offloads Two German OTC Brands, New CEO Prepares To Make Mark

Reckitt Invests In AI Symptom Checker To ‘Unlock Self-Care’

GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes

IXICO Targets Go-To Status In Neuro Data Analytics Space

Novo Nordisk’s Oral Rybelsus Priced On Par With Injectable GLP-1s, But Big Discounts May Be Needed

Why Deals Fail: The Reasons May Be Clinical, Economic Or Strategic

Biotech CEOs: Can Scientist-Founders Remain In Charge?

House Committee Hearing Shows How Talc/Asbestos Concerns Could Be Impetus For Cosmetics Reform

The Knowledge Within: An Interview With Merck KGaA’s R&D Chief

How Roche Won The Bidding Battle For Spark

Gene Therapy Investment At All Time High, Commercialization Challenges Noted

BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says